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Background: Guillain-Barré syndrome (GBS) is an autoimmune condition characterized by peripheral neuropathy.
The pathogenesis of GBS is not fully understood, and the mechanism of how intravenous immunoglobulin (IVIG)
cures GBS is ambiguous. Herein, we investigated lymphocyte subsets in patients with two major subtypes of GBS
(acute inflammatory demyelinating polyneuropathy, AIDP, and acute motor axonal neuropathy, AMAN) before and
after treatment with IVIG, and explored the possible mechanism of IVIG action.
Methods: Sixty-four patients with GBS were selected for our study and divided into two groups: AIDP (n = 38) and
AMAN (n = 26). Thirty healthy individuals were chosen as the control group. Relative counts of peripheral blood T and
B lymphocyte subsets were detected by flow cytometry analysis.
Results: In the AIDP group, the percentage of CD4+CD45RO+ T cells was significantly higher, while the
percentage of CD4+CD45RA+ T cells was notably lower, than in the control group. After treatment with IVIG,
the ratio of CD4+/CD8+ T cells and the percentage of CD4+CD45RA+ T cells increased, while the percentages of
CD8+ T cells and CD4+CD45RO+ T cells decreased significantly, along with the number of CD19+ B cells.
However, there were not such obvious changes in the AMAN group. The Hughes scores were significantly
lower in both the AIDP and AMAN groups following treatment with IVIG, but the changes in Hughes scores
showed no significant difference between the two groups.
Conclusions: This study suggested that the changes in T and B-lymphocyte subsets, especially in CD4+T-lymphocyte
subsets, might play an important role in the pathogenesis of AIDP, and in the mechanism of IVIG action against AIDP.
Keywords: Acute inflammatory demyelinating polyneuropathy, Acute motor axonal neuropathy, Guillain-Barré syndrome,
Intravenous immunoglobulin, Lymphocyte subsetsBackground
Guillain-Barré syndrome (GBS) is an acute, immune-
mediated attack on the peripheral nervous system that
leads to flaccid paralysis, with a case fatality rate of 5–10%
[1]. Both cellular and humoral immunity participate in the
onset of GBS, though cellular immunity is the primary
cause [2]. Based on clinical, electrophysiological, and
pathologic characteristics, GBS can be divided into two
major subtypes: AIDP (acute inflammatory demyelinat-
ing polyneuropathy, AIDP) and AMAN (acute motor* Correspondence: guoli6105@163.com
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unless otherwise stated.axonal neuropathy, AMAN) [3]. At present there is no
specific treatment for GBS; intravenous immunoglobu-
lin (IVIG) has been the drug of choice for GBS treat-
ment because it provides the most effective clinical
results [4,5], with almost no contraindications.
Lymphocyte function is related to the numerous com-
plex superficial cell membrane proteins on the cell sur-
face. As a result, lymphocyte immune phenotype analysis
can be used as an important reference index for evaluating
the body’s immune status. In recent years, much work has
been undertaken to study the distribution of lymphocyte
subsets in GBS, but the results are variable [6-9]. Our
team found that the distribution of lymphocyte subsets
differs greatly between individuals; therefore, it is important. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hou et al. BMC Neurology 2014, 14:202 Page 2 of 7
http://www.biomedcentral.com/1471-2377/14/202to test individual GBS patients both before and after IVIG
treatment [5]. In the current study, we examined GBS in a
population of individuals from northern China who devel-
oped AIDP or AMAN. This study used a matched-pairs
design using each patient’s own pre- and post-treatment
data. We detected changes in T and B lymphocyte subset
distribution, allowing us to explore the pathogenesis of




All subjects (patients with AIDP or AMAN and healthy
controls) were from northern China and were referred
to the Second Hospital of Hebei Medical University in
Shijiazhuang from 2010–2013. All patients fulfilled ac-
cepted diagnostic criteria [10], and were studied within
2 weeks of the onset of GBS. Sixty-four cases under-
went electrophysiological examination, being recorded
for motor conductive velocity (MCV), distal latency, F wave,
and motor evoked amplitude [10-13], and were classified
into two groups: AIDP (n =38) and AMAN (n =26). The
primary outcome parameter was GBS disability (Hughes)
scale score at discharge. Thirty subjects (age- and sex-
matched controls) from the same area were also in-
cluded in the study. Controls had no personal or family
history of GBS, and no sign of any peripheral neur-
opathy. Controls were chosen randomly.
Peripheral blood was collected and T and B lympho-
cyte subset relative counts were detected by flow cytom-
etry both before and after treatment with IVIG. This
study protocol was approved by the Research Ethics
Committee of the Second Hospital of Hebei Medical
University and followed the ethical guidelines of the
1975 Declaration of Helsinki and all subsequent modifi-
cations [14]. All patients provided a written informed
consent to participate in this research.
Therapeutic method
Patients were treated with IVIG (0.4 g·kg−1·d−1) continu-
ously for 5 days. At 3 weeks post-therapy, patients were
again graded using the Hughes scale [15,16].
Flow cytometry
Prior to therapy, and again within 24 hours of the final
therapy with IVIG, whole blood was collected in EDTA
vacutainer tubes. Cyflow reagents and consumables
were used according to the manufacturer’s protocol.
The set comprised the following antibodies: CD4-APC/
CD8-PE/CD3-FITC; CD4-APC/CD45RA-FITC/CD45RO-
PE; CD19-FITC (Becton Dickinson, San Jose, CA, USA).
Meanwhile, IgG1-FITC/IgG2a-PE was replied as isotype
control. 100 μl of the blood was incubated in tubes to-
gether with 20 μl of the antibodies. The incubation wasperformed in the dark, at room temperature for 15 min.
After incubation, erythrocytes were subsequently lysed,
and the cell suspension was centrifuged, washed three
times, and resuspended in an appropriate volume of flow
staining buffer. A minimum of 10,000 cells was accepted
for FACS (BD Biosciences, San Jose, CA, USA) analysis.
Cells were gated based on morphological characteristics.
Analysis
Statistical analyses were conducted using SPSS18.0 soft-
ware, and continuous variables are expressed as mean ±
standard deviation ( x  s ). The mean differences be-
tween the two samples were analyzed using a t-test. The
mean differences between the two patient groups before
and after treatment were compared using a paired t-test.
The inspection level was α =0.05 and differences were
considered significant at p <0.05.
Results
The percentage of CD4+CD45RO+ T cells (65.60 ± 10.41
vs 55.06 ± 5.48) was significantly higher, while the percent-
age of CD4+CD45RA+ T cells (29.10 ± 10.13 vs 39.24 ±
6.25) was obviously lower (p <0.05), in the AIDP group
than in the control group, but there was no significant dif-
ference between samples drawn from the AMAN group
(Figures 1 and 2).
In the AIDP group, the ratio of CD4+/CD8+ T cells
(1.85 ± 1.09 vs 1.29 ± 0.80) and the percentage of CD4+
CD45RA+ T cells (37.56 ± 9.22 vs 29.10 ± 10.13) increased
significantly (p <0.05), while the percentage of CD8+ T
(29.60 ± 7.90 vs 35.12 ± 11.94), CD4+CD45RO+ T (57.51 ±
8.45 vs 65.60 ± 10.41), and CD19+ B (12.11 ± 4.58 vs
15.89 ± 3.41) cells significantly decreased (p <0.05) after
treatment. Again, there was not such a marked change
following treatment in the AMAN group (Figures 3, 4,
and 5).
The Hughes scores were significantly lower in both
the AIDP and AMAN groups following treatment with
IVIG (p <0.05) (Table 1).
The change in Hughes scores was 1.95 ± 0.56 in the
AIDP group and 1.73 ± 0.80 in the AMAN group, and
there was no significant difference between the two
groups (p >0.05).
Discussion
Demyelination of motor and sensory nerves occurs in
AIDP, whereas motor neurons evoke reduced amplitudes
in AMAN, without demyelination. AIDP is an autoimmune
disorder mediated by T and B lymphocyte systems. Patho-
logically, varying degrees of lymphocyte infiltration [17]
and myelin sheath depigmentation can be found in AIDP,
and the complement-mediated antibody attack on nerves is
likely to play an important role in the pathogenesis of AIDP
[18]. In AMAN, motor nerve axons, especially in Ranvier’s
Figure 1 Comparison of lymphocyte subsets in AIDP and control groups before treatment. The data are mean ± S.D. *p <0.05, relative to
the control group.
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of Wallace degeneration, but rarely with inflammation and
demyelination [19,20]. The etiology of GBS is not clear;
however, a possible relationship with certain infections and
vaccination has been documented in several studies [21-23].
GBS frequently follows a variety of presumed viral and bac-
terial infections [24,25], and Campylobacter gastroenteritis
is the single most identifiable agent associated with GBS
(AMAN) [26]. In subjects with GBS from northern China
who developed AIDP and AMAN, the DNA-based typing
of the HLA class II alleles in the two subtypes demonstrated
that HLA class II epitopes are not distributed equally [27].
According to their antigen recognition receptors, T lym-
phocytes can be classified into two groups: TCR α/β T cells
and TCR γ/δ T cells. The former make up more thanFigure 2 Comparison of lymphocyte subsets in AMAN and control gr90% of T cells in peripheral blood. TCR α/β T cells,
which are composed of CD3+CD4+CD8− T cells and
CD3+CD4−CD8+ T cells, play an important role in com-
mon immune response. γ/δ T cells were discovered in the
past decade, and make up 0.5–10% of T cells in peripheral
blood. Most γ/δ T cells express CD3+CD4−CD8−T, which
can be activated in autoimmune diseases. T lymphocytes
include helper T lymphocytes (CD4+T) and killer T lym-
phocytes (CD8+T). CD4+ T cells are heterogeneous, and
include naive T cells and memory T cells, the former pre-
dominately expressing CD45RA and the latter expressing
CD45RO [28,29]. In different stages of T cell development,
different CD45 subtypes are expressed. Studies have
shown that during the development of T cells in the
thymus, a shift from CD45RO to CD45RA occurs, whichoups before treatment. The data are mean ± S.D.
Figure 3 Comparison of lymphocyte subsets in AIDP before and after treatment. The data are mean ± S.D. *p <0.05.
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eliminate autoreactive T cells and prevent autoimmune
disease [30]. In the peripheral blood, CD4+CD45RA+ T cells
can convert into CD4+CD45RO+ T cells following stimula-
tion by antigen [30]. CD45RA and CD45RO have distinct
effects on the function of B cells, and B cells can also
increase the proliferation of CD45RO, in contrast to a
decreased proliferation of CD45RA [31]. CD19 is an
idioantigen of B lymphocytes, which also participates
in their activation and signal conduction.
Our previous investigation found that if the number of
CD4+ T or CD8+ T cells, or the ratio between them,
changed, then immune functions may become disor-
dered leading to a disease state in patients with GBS [5].
Studies have also shown that the number of CD4+ T cells in
patients with GBS decreased while CD8+ T cells increased,Figure 4 Comparison of lymphocyte subsets in AMAN before and aftespecially in the progressive stage. More specifically,
CD4+CD29+ T cells (assist/induction of CD4+ T cells)
increased and CD4+CD45RA+ T cells (restrain/induc-
tion of CD4+ T cells) decreased [6,7]. In contrast, other
studies reported that the number of CD4+ T cells in
patients with GBS increased and CD8+ T cells de-
creased [8,9]. Our previous study showed that following
treatment with IVIG, CD8+ T and CD4+CD29+ T cells de-
creased in patients with GBS, whereas CD4/CD8 and
CD4+CD45RA+ T cells increased [5]. To understand
the changes in lymphocyte subsets in different subtypes of
GBS, we carried out a further study and divided GBS
patients into AIDP and AMAN groups.
In AIDP, demyelination and lymphocyte infiltration
are observed. However, there is very little inflammation
and demyelination in AMAN. Our research showed thater treatment. The data are mean ± S.D.
Figure 5 Representative plots from individual patient from AIDP group, gated on CD4+. The number in each quadrant represents CD45RA
and CD45RO gated on CD4+.
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were different. In the AIDP group, the percentage of
CD4+CD45RA+ T cells was markedly lower, whereas the
percentage of CD4+CD45RO+ T cells was significantly
higher than in the control group. The reason for this may
be that CD4+CD45RA+ T cells transformed into CD4
+CD45RO+ T cells after activation by antigens in the per-
ipheral blood. This result is consistent with a study that
showed that CD45RO enters into the cell cycle earlier
than CD45RA stimulated by growth factors [32]. The
transformation suggested that cellular immunology, espe-
cially the change in CD4+ T cell subsets, might play an im-
portant role in the pathogenesis of AIDP.
Cortical hormone has been the drug of choice to treat
GBS. However, research has shown that routine hor-
mone treatment cannot prevent the progression of GBS
or improve prognosis [33]. At present, large doses of
IVIG are the foremost immunoregulatory therapeutic
method, and can ameliorate the course of GBS progression
[5,34]. After therapy with IVIG, the ratio of CD4+/CD8+
T and the percentage of CD4+CD45RA+ T cells increased,
while the percentage of CD8+ T, CD4+CD45RO+ T, and
CD19+ B cells significantly declined in the AIDP group.Table 1 Comparison of Hughes scores before and after
treatment in each group (x ± s)
Group Time Hughes score
AIDP Before treatment 3.59 ± 0.45
(n = 38) After treatment 1.32 ± 0.67
Falling value 2.27
p <0.05
AMAN Before treatment 4.12 ± 0.63
(n = 26) After treatment 2.47 ± 0.82
Falling value 1.65
p <0.05
-We presumed that IVIG inhibited the toxic effects of CD8
killer T cells on the myelin of nerves in AIDP and by alter-
ing the distribution of CD8+ T, CD4+CD45RA+ T, and
CD4+CD45RO+ T cells, IVIG reduced the total number of
B lymphocytes. Therefore, IVIG might affect the produc-
tion of autoantibodies and decrease inflammatory cell infil-
tration, and we found Hughes scale score was significantly
lower after treatment, this result suggested IVIG could
suppress peripheral nerve injury and encourage neurofunc-
tional recovery mediated by increasing CD45RA T cell and
decreasing CD45RO Tcell.
In the AMAN group, changes were not significant. That
is, less inflammation and demyelination were present. Al-
though IVIG suppressed immune reactions to a certain
degree and prevented aggravation of the condition, our
study showed no association between the immune param-
eters investigated and IVIG. These findings hint that there
might be other changes in immune function, and further
studies are needed.
The Hughes scale score was significantly lower both in
the AIDP and AMAN groups after therapy with IVIG,
and the change in the score was not significantly differ-
ent between the AIDP and AMAN groups. Although
this study cannot explain the pathogenicity of AMAN
and the mechanism by which IVIG treats it, the effect of
IVIG curing AMAN is evident. Therefore, in our clinical
setting, we propose administering full doses of IVIG to
patients with AIDP and AMAN at the earliest stage.
This might prevent aggravation of the condition, de-
crease paralysis of respiratory muscle, prevent tracheal
incision, preclude complications, and encourage the re-
covery of function of damaged neurology as soon as
possible.
A search of the literature found very different conclu-
sions on lymphocyte subgroup detection in patients with
GBS. We designed this study of GBS patients to make
patients their own controls, before and after treatment.
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uals who have suffered from infection previously. Fur-
thermore, it can reveal the impact of disease and IVIG
intervention on the immune system of an individual.
GBS can be classified into two major groups: AIDP and
AMAN. These groups differ in their hematological and
immunological pathogenesis. Consequently, when study-
ing lymphocyte subsets in GBS, it is important to classify
GBS into AIDP or AMAN, and use patients as their
own controls, before and after treatment, to minimize
the effects of variation on the results.
Conclusions
This study suggested that the changes in CD4+T-lymphocyte
subsets might play an important role in the pathogenesis
of AIDP. After treatment with IVIG, the changes in T and
B-lymphocyte subsets are significant and also might play
an important role in the mechanism of IVIG action
against AIDP. But there were not such changes in AMAN,
this study might infer that the pathogenesis and the mech-
anism of IVIG action against two subjects of GBS(AIDP
and AMAN) are different and further studies are needed
to expound these problems.
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